Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients

Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrint's ability to identify strongest candidates for extended endocrine therapy among HR+HER2-

Related Keywords

Kostenloser Wertpapierhandel ,Gerrit Jan Liefers ,Kerry Harrington ,Agendia Inc ,Linkedin ,Professor Of Laboratory Medicine ,Facebook ,Antonio Breast Cancer Symposium ,Laboratory Medicine ,Applied Genomics ,California San Francisco ,Helen Diller Family Comprehensive Cancer Center ,Mammaprint Low Risk ,Mammaprint High Risk ,Mammaprint Ultralow Risk ,Geriatric Oncology Group ,Leiden University Medical Center ,Agendia ,Level ,Evidence ,Shows ,Mammaprint ,First ,Only ,Leared ,Gene ,Expression ,Profiling ,Pest ,Redict ,Benefit ,Rom ,Xtended ,Ndocrine ,Therapy ,Early ,Stage ,Breast ,Dancer ,Patients ,